Contact SCGE




SCGE Consortium Home   |  About SCGE Toolkit   |  Contact Us   |  Citing the Toolkit   |  License  
Home

Project: Delivery Technologies for In Vivo Genome Editing

PI:   Elliot L. Chaikof, MD, PhD NIH Report

The difficulty of delivering genome editing agents into many types of cells in animals and patients is a major challenge that must be overcome to realize their full potential to cure genetic diseases. We propose to develop two new strategies for the delivery of genome editing agents into animals and patients that will increase editing efficiency, target cell selectivity, and DNA specificity, as well as a new tool to rapidly and sensitively evaluate the delivery of these agents in mice with minimal effort and expense. These developments will advance the safety and efficacy of genome editing methods for clinical development.
Summary of data submissions:
  • Data for 2  experiments were submitted on 2022-04-15 SCGE ID:1059
  • 1 of 2 experiments have been validated

Submissions Details

SCGE ID:1059 - Submission Date: 2022-04-15 
Experiment Name Type Description
Pcsk9 adenine base editor efficiency in liver and nonliver tissue

In Vivo Adenine base editing at the Pcsk9 exon 1 splice donor site in mouse heart, kidney, liver, lungs, muscle, and spleen was assessed one week after systemic administration of an adenine base editor delivered by engineered virus-like particles (BE-eVLPs) in C56BL/6 mice
On-target editing compared to 14 circle-seq nominated off-target sites of adenine base editor delivered by BE-eVLP vs AAV in the C57BL/6 liver

In Vivo On-target editing compared to off-target editing at 14 CIRCLE seq nominated sites in livers of an adenine base editor delivered by engineered virus-like particles (BE-eVLPs). Treated mice vs. untreated vs. AAV was assessed one week after systemic administration of BE-eVLPs or AAV-Pcsk9 to C57BL/6 mice. DNA sequencing reads containing A-T to G-C mutations within protospacer positions 4-10.